PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Nicolas GuibertAnne Pradines

Abstract

Inhibitors of the PD-1/PD-L1 immune checkpoint have become a standard of care in non-small cell lung cancer (NSCLC). Patient selection, currently based on PD-L1 expression on tumor tissue, is limited by its temporal and spatial heterogeneity. We hypothesized that liquid biopsy with PD-L1 analysis on circulating tumor cells (CTCs) might overcome this limitation. Blood samples were prospectively collected from patients with advanced NSCLC before nivolumab treatment and at the time of progression. CTCs were isolated using a cell size-based technology. PD-L1 expression was assessed by immunofluorescence on CTCs and immunohistochemistry on tissue biopsies. 113 specimens from 96 patients were collected. Baseline PD-L1 expression could be assessed on 72% and 93% of tissue and CTC, respectively. CTCs were more frequently found to be PD-L1 positive than tissue (83% vs. 41%) and no correlation was observed between tissue and CTC PD-L1 expression (r = 0.04, p = 0.77). Pre-treatment high CTC number was associated with increased risk of death and progression (HR1.06, p = 0.03 for OS; HR1.05, p = 0.02 for PFS). The presence of pre-treatment PD-L1+CTC was not significantly correlated with outcomes but a higher baseline PD-L1+ CTC number (≥1%)...Continue Reading

Citations

May 20, 2019·Radiology and Oncology·Taja LozarTanja Jesenko
May 3, 2019·Journal of Pathology and Translational Medicine·Hyojin Kim, Jin-Haeng Chung
Jun 23, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P HofmanK Pantel
Aug 30, 2019·Cells·Elisabetta Rossi, Francesco Fabbri
Dec 22, 2019·Cancers·Erika RijavecFrancesco Grossi
Dec 8, 2019·Clinical Chemistry·Luis Enrique Cortés-HernándezCatherine Alix-Panabières
Oct 15, 2019·Expert Review of Molecular Diagnostics·Alessandro RussoChristian Rolfo
May 31, 2020·Cancers·Drahomír KolenčíkPeter Kuhn
May 29, 2020·Journal of Experimental & Clinical Cancer Research : CR·Marco RussanoDaniele Santini
Aug 5, 2020·JCO Global Oncology·Abdul Rahman JaziehWalid E Khalbuss
Dec 14, 2018·Experimental & Molecular Medicine·Pramod DarvinEyad Elkord
Mar 21, 2019·Frontiers in Oncology·Jatta SaarenheimoAntti Jekunen
Jul 16, 2019·Expert Review of Molecular Diagnostics·Marianna GalloNicola Normanno
Dec 20, 2018·Cancer Medicine·Arutha KulasingheChamindie Punyadeera
Dec 24, 2019·Frontiers in Medicine·Joanna Domagala-Kulawik
Feb 14, 2020·European Respiratory Review : an Official Journal of the European Respiratory Society·Nicolas GuibertJulien Mazieres
Mar 21, 2020·Genome Medicine·Francesc Castro-Giner, Nicola Aceto
Aug 23, 2020·International Journal of Molecular Sciences·Ana BocanegraGrazyna Kochan
Jul 20, 2020·International Journal of Cancer. Journal International Du Cancer·Isabel HeidrichKlaus Pantel
Aug 29, 2019·Nature Reviews. Cancer·Laura Keller, Klaus Pantel
Aug 30, 2018·Frontiers in Oncology·Joanna KapelerisChamindie Punyadeera
Aug 28, 2020·Frontiers in Bioengineering and Biotechnology·Binsheng HeGeng Tian
Oct 6, 2020·Scandinavian Journal of Immunology·Andreas HallqvistSukanya Raghavan
Oct 29, 2020·Cancer Immunology, Immunotherapy : CII·Elena María Brozos-VázquezRafael López-López
Apr 15, 2020·Cancer Cell·Elaine KilgourCaroline Dive
Jan 16, 2021·Molecular Oncology·Mahmoud Labib, Shana O Kelley
Feb 14, 2021·Nature Reviews. Clinical Oncology·Deborah Blythe DoroshowFred R Hirsch
Mar 17, 2019·Pharmacology & Therapeutics·Asurayya WorredeAlessandro Fatatis
Mar 7, 2021·Genes·Ivana MartinsIsabel Marques Carreira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

© 2022 Meta ULC. All rights reserved